



# Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application

## Guidance for Industry

### ***DRAFT GUIDANCE***

**This guidance document is being distributed for comment purposes only.**

Comments and suggestions regarding this draft document should be submitted within 90 days of publication in the *Federal Register* of the notice announcing the availability of the draft guidance. Submit electronic comments to <http://www.regulations.gov>. Submit written comments to the Division of Dockets Management, Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number listed in the notice of availability that publishes in the *Federal Register*.

For questions regarding this draft document contact Leah Christl (CDER) at 301-796-0869 or the Office of Communication, Outreach, and Development (CBER) at 800-835-4709 or 240-402-7800.

**U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research (CDER)  
Center for Biologics Evaluation and Research (CBER)**

**February 2015  
Compliance**

# Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application

## Guidance for Industry

*Additional copies are available from:  
Office of Communications, Division of Drug Information  
Center for Drug Evaluation and Research*

*Food and Drug Administration  
10001 New Hampshire Ave., Hillandale Bldg., 4<sup>th</sup> Floor  
Silver Spring, MD 20993-0002  
Phone: 8855-543-3784 or 301-796-3400; Fax: 301-431-6353  
Email: [druginfo@fda.hhs.gov](mailto:druginfo@fda.hhs.gov)*

*<http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm>*

*Office of Communication, Outreach, and Development  
Center for Biologics Evaluation and Research  
Food and Drug Administration*

*10903 New Hampshire Ave., Building 71, Room 3128  
Silver Spring, MD 20993  
Phone: 800-835-4709 or 240-402-7800*

*Email: [ocod@fda.hhs.gov](mailto:ocod@fda.hhs.gov)*

*<http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/default.htm>*

**U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research (CDER)  
Center for Biologics Evaluation and Research (CBER)**

**February 2015  
Compliance**

*Contains Nonbinding Recommendations*  
*Draft — Not for Implementation*

**TABLE OF CONTENTS**

<b>I.</b>	<b>INTRODUCTION AND SCOPE .....</b>	<b>1</b>
<b>II.</b>	<b>BACKGROUND .....</b>	<b>3</b>
<b>A.</b>	<b>Biological Products .....</b>	<b>3</b>
<b>B.</b>	<b>Legal Framework for FDA’s Regulation of Biological Products.....</b>	<b>5</b>
<b>C.</b>	<b>Sections 503A and 503B of the FD&amp;C Act Do Not Exempt Biological Products from the Premarket Approval Requirements of the PHS Act or from Provisions of the FD&amp;C Act .....</b>	<b>5</b>
<b>D.</b>	<b>Hospital and Health System Repackaging of Drugs In Shortage For Use in the Health System (Section 506F of the FD&amp;C Act) .....</b>	<b>6</b>
<b>III.</b>	<b>POLICY .....</b>	<b>7</b>
<b>A.</b>	<b>General Conditions .....</b>	<b>7</b>
<b>B.</b>	<b>Mixing, Diluting, or Repackaging Licensed Biological Products .....</b>	<b>7</b>
<b>C.</b>	<b>Licensed Allergenic Extracts .....</b>	<b>12</b>
	<b>APPENDIX 1 – MICROBIAL CHALLENGE STUDY DESIGN.....</b>	<b>16</b>

*Contains Nonbinding Recommendations*  
*Draft — Not for Implementation*

1 **Mixing, Diluting, or Repackaging Biological Products Outside the**  
2 **Scope of an Approved Biologics License Application**  
3 **Guidance for Industry<sup>1</sup>**  
4

5  
6 This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's or the  
7 Agency's) current thinking on this topic. It does not create or confer any rights for or on any person and  
8 does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies  
9 the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach,  
10 contact the FDA staff responsible for implementing this guidance. If you cannot identify the appropriate  
11 FDA staff, call the appropriate number listed on the title page of this guidance.  
12

13  
14 **I. INTRODUCTION AND SCOPE**  
15

16 This guidance sets forth FDA's policy regarding the mixing,<sup>2</sup> diluting, and repackaging<sup>3</sup> of  
17 certain types of biological products that have been licensed under section 351 of the Public  
18 Health Service Act (PHS Act) when such activities are not within the scope of the product's  
19 approved biologics license application (BLA) as described in the approved labeling for the  
20 product.<sup>4</sup> This guidance describes the conditions under which FDA does not intend to take action  
21 for violations of sections 351 of the PHS Act and sections 502(f)(1) and where specified, section  
22 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), when a state-licensed  
23 pharmacy, a Federal facility, or an outsourcing facility<sup>5</sup> dilutes, mixes or repackages certain  
24 biological products without obtaining an approved BLA.

---

<sup>1</sup> This guidance has been prepared by multiple offices in the Center for Drug Evaluation and Research (CDER), in cooperation with the Center for Biologics Evaluation and Research (CBER), and the Office of Regulatory Affairs at the Food and Drug Administration.

<sup>2</sup> For purposes of this guidance, mixing means combining an FDA-licensed biological product with one or more ingredients. Not covered by this guidance is diluting or mixing a biological product at the point of care for immediate administration to a single patient after receipt of a patient specific prescription or order for that patient (e.g., diluting or mixing into a syringe to administer directly to the patient).

<sup>3</sup> For purposes of this guidance, repackaging means taking a licensed biological product from the container in which it was distributed by the original manufacturer and placing it into a different container without further manipulation of the product. As used in this guidance, the terms mixing, diluting, and repackaging describe distinct sets of activities with respect to a biological product.

<sup>4</sup> This guidance does not apply to blood and blood components for transfusion, vaccines, cell therapy products, and gene therapy products

<sup>5</sup> "Outsourcing facility" refers to a facility that meets the definition of an outsourcing facility under section 503B(d)(4) of the FD&C Act. See FDA's draft guidance, "Guidance for Entities Considering Whether to Register As Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act."

***Contains Nonbinding Recommendations****Draft — Not for Implementation*

- 25 This guidance **does not address** the following:
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- Biological products not subject to licensure under section 351 of the PHS Act (i.e., biological products for which a marketing application could properly be submitted under section 505 of the FD&C Act (see section 7002(e) of the Affordable Care Act)). The repackaging of biological products not subject to licensure under section 351 is addressed in a separate draft guidance document.<sup>6</sup>
  - Products intended for use in animals. FDA will consider addressing this issue in a separate guidance document.
  - Mixing, diluting, or repackaging biological products (other than allergenic extracts) by entities that are not state-licensed pharmacies, Federal facilities, or outsourcing facilities; and preparation of allergenic extracts by entities that are not state-licensed pharmacies, Federal facilities, outsourcing facilities, or physicians (See additional information in section III.A. of this draft guidance document).
  - Removing a biological product from the original container at the point of care for immediate administration to a single patient after receipt of a patient-specific prescription or order for that patient (e.g., drawing up a syringe to administer directly to the patient). FDA does not consider this to be “repackaging,” for purposes of this guidance document.
  - Upon receipt of a patient-specific prescription, a licensed pharmacy removing from one container the quantity of solid oral dosage form biological products necessary to fill the prescription and placing it in a smaller container to dispense directly to its customer.
  - Mixing, diluting, or repackaging a licensed biological product when the product is being mixed, diluted, or repackaged in accordance with the approved BLA as described in the approved labeling for the product. FDA considers this to be an approved manipulation of the product.
  - Mixing, diluting, or repackaging of blood and blood components for transfusion,<sup>7</sup> vaccines, cell therapy products, or gene therapy products (see footnote 4). The guidance does not alter FDA’s existing approach to regulating the collection and processing of blood and blood components. In addition, FDA intends to consider regulatory action if licensed vaccines, cell therapy products, and gene therapy products are subject to additional manufacturing, including mixing, diluting, or repackaging, in ways not specified in the product’s approved BLA as described in the approved labeling for the product.
- As stated above, this guidance does not address the mixing, diluting, or repackaging of a biological product for which a marketing application could properly be submitted under section 505 of the FD&C Act (see section 7002(e) of the Affordable Care Act). Accordingly, the term

---

All FDA guidances are available on the Agency’s guidance website at <http://www.fda.gov/ForIndustry/FDABasicsforIndustry/ucm234622.htm>. FDA updates guidances regularly. To ensure that you have the most recent version, please check this web page.

<sup>6</sup> The repackaging of biological products approved under section 505 is addressed in a separate draft Guidance, “*Repackaging of Certain Human Drug Products by Pharmacies and Outsourcing Facilities*.”

<sup>7</sup> The guidance does apply to licensed biological products that are plasma derived products, including recombinant and transgenic versions of plasma derivatives, mixed, diluted, or repackaged outside the scope of an approved BLA.

***Contains Nonbinding Recommendations****Draft — Not for Implementation*

61 “*biological product*” as used in this guidance does not include products for which a marketing  
62 application can be or has been submitted under section 505 of the FD&C Act.

63  
64 Section II of this guidance provides background on biological products and the legal framework  
65 for FDA’s regulation of these products, and explains that sections 503A and 503B of the FD&C  
66 Act do not provide exemptions for mixing, diluting, or repackaging of biological products.  
67 Section III describes FDA’s policy on mixing, diluting, or repackaging of certain licensed  
68 biological products that is not within the scope of the product’s approved BLA as described in  
69 the approved labeling for the product.

70  
71 FDA’s guidance documents, including this guidance, do not establish legally enforceable  
72 responsibilities. Instead, guidances describe the Agency’s current thinking on a topic and should  
73 be viewed only as recommendations, unless specific regulatory or statutory requirements are  
74 cited. The use of the word *should* in Agency guidances means that something is suggested or  
75 recommended, but not required.

76  
77 **II. BACKGROUND**

78  
79 **A. Biological Products**

80  
81 The term “biological product” is defined in section 351(i)(1) of the PHS Act to mean:

82  
83 a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood component or  
84 derivative, allergenic product, protein (except any chemically synthesized  
85 polypeptide), or analogous product, or arsphenamine or derivative of  
86 arsphenamine (or any other trivalent organic arsenic compound), applicable to  
87 the prevention, treatment, or cure of a disease or condition of human beings.

88  
89 Biological products can be complex chains or combinations of sugars, amino acids, or nucleic  
90 acids, or living entities such as cells and cellular therapies. Biological products include  
91 therapeutic proteins, monoclonal antibodies, allergenic extracts, blood and blood derivatives, cell  
92 therapy products, and gene therapy products, preventive vaccines, and therapeutic vaccines.  
93 Generally, biological products have a complex set of structural features (e.g., amino acid  
94 sequence, glycosylation, folding) essential to their intended effect, and are very sensitive to  
95 changes to their manufacturing process, including, but not limited to, any manipulation outside  
96 of their approved container-closure systems. In addition, many biological products are  
97 particularly sensitive to storage and handling conditions and can break down or aggregate if  
98 exposed to heat and/or light, if dropped, or if shaken during storage and handling. Accordingly,  
99 diluting or mixing a biological product with other components, or repackaging a biological  
100 product by removing it from its approved container-closure system and transferring it to another  
101 container-closure system, is, in the absence of manufacturing controls, highly likely to affect the  
102 safety and/or effectiveness of the biological product.

103  
104 Nevertheless, certain licensed biological products may need to be mixed or diluted in a way not  
105 described in the approved labeling for the product to meet the needs of a specific patient. For  
106 example, for some biological products there is no licensed pediatric strength and/or dosage form,  
107 so the product must be diluted for use in pediatric patients. In addition, there may be certain

***Contains Nonbinding Recommendations****Draft — Not for Implementation*

108 circumstances where a person would repackaging a licensed biological product by removing it  
109 from its original container and placing it into a different container(s), in a manner that is not  
110 within the scope of the approved BLA as described in the approved labeling for the product.  
111 Like other drugs, biological products are sometimes repackaged for various reasons including for  
112 pediatric or ophthalmic use. For example, a pediatric dialysis unit may repackaging a larger  
113 quantity of a product into smaller aliquots so that the optimal dose may be administered to each  
114 pediatric dialysis patient being treated at that particular time.

115  
116 Repackaging a drug or biological product could change its characteristics in ways that have not  
117 been evaluated during the approval process and that could affect the safety and effectiveness of  
118 the product. Improper repackaging of drug and biological products can cause serious adverse  
119 events. Of particular concern is the repackaging of sterile drugs, which are susceptible to  
120 contamination and degradation. For example, failure to properly repackaging a sterile drug under  
121 appropriate aseptic conditions could introduce contaminants that could cause serious patient  
122 injury or death. Repackaging practices that conflict with approved product labeling have led to  
123 product degradation resulting in adverse events associated with impurities in the product or lack  
124 of efficacy because the active ingredient has deteriorated. These risks are often even more acute  
125 for biological products due to their complex composition and sensitivity to variations in storage  
126 and handling conditions.

127  
128 Cell and gene therapy products often contain viable cells or intact/active viral vectors. The  
129 manufacturing process for these products is complex and includes multiple controls to assure the  
130 purity or potency of the product and its safety and effectiveness. Many cell therapy products are  
131 cryopreserved, and the procedures for thawing and handling in preparation for administration  
132 described in the approved labeling must be followed to maintain the safety and effectiveness of  
133 the product. In addition, because these products are frequently implanted or administered  
134 intravenously and are not typically amenable to terminal sterilization, their microbiological  
135 safety is dependent largely on facility design, aseptic technique, and manufacturing protocols  
136 that are best controlled by robust quality systems.

137  
138 Vaccines are manufactured using biological systems and supplied by manufacturers in single  
139 dose or multi-dose presentations. Unlike most other drugs and biological products, vaccines are  
140 administered to healthy individuals, including infants, to prevent disease. Vaccines may contain  
141 live attenuated organisms, inactivated organisms, or components of bacteria or viruses such as  
142 polysaccharides, inactivated toxins, or purified proteins. The manufacturing process for  
143 vaccines is complex and includes multiple controls to assure safety and effectiveness. Each  
144 single dose of a vaccine is formulated to deliver the correct quantity of active ingredient(s) to the  
145 recipient.

146  
147 The policies in this guidance do not cover cell therapy products, gene therapy products, and  
148 vaccines. Because of the particularly sensitive nature of these products as described above, these  
149 categories of products must be prepared, and if applicable to that product's use, repackaged,  
150 under an approved BLA, in accordance with section 351 of the PHS Act.

151  
152 The policies in this guidance also do not cover or alter FDA's existing approach to regulating the  
153 collection and processing of blood and blood components for transfusion. These activities are

**Contains Nonbinding Recommendations***Draft — Not for Implementation*

154 currently conducted in FDA licensed or registered blood collection establishments and in  
155 hospital-based transfusion services regulated in part by the Centers for Medicare and Medicaid  
156 Services under the Clinical Laboratory Improvement Amendments of 1988. In all instances,  
157 blood collection and processing is already subject to current good manufacturing practices  
158 (CGMP) under the existing statutory and regulatory framework for blood and blood components  
159 and will not be subject to the policies described here.

160

161

**B. Legal Framework for FDA’s Regulation of Biological Products**

162

163 Section 351(a)(1) of the PHS Act prohibits the introduction into interstate commerce of any  
164 biological product unless “a biologics license... is in effect for the biological product.” For FDA  
165 to approve a BLA, the BLA must contain data to demonstrate that the biological product is safe,  
166 pure, and potent and that the facility in which the biological product will be manufactured,  
167 processed, packed, or held meets standards designed to ensure that the biological product  
168 continues to be safe, pure, and potent. Because manufacturing controls are so important to  
169 ensuring the safety and effectiveness of biological products, FDA licensing of a biological  
170 product is based, in part, on an extensive review of chemistry and manufacturing controls data  
171 submitted by the applicant. This includes a thorough evaluation of the raw materials, drug  
172 substance, and drug product to ensure consistency in manufacturing and continued safety and  
173 effectiveness. In addition, other data are submitted and reviewed (e.g., stability and  
174 compatibility testing results) to establish the storage and handling conditions appropriate to  
175 ensure the safety, purity, and potency of the biological product.

176

177 A biological product that is mixed, diluted, or repackaged outside the scope of an approved BLA  
178 is an *unlicensed biological product* under section 351 of the PHS Act. For example, if a licensed  
179 biological product is diluted or mixed with components other than those described in the  
180 approved labeling for the product, or if it is removed from its original container-closure system  
181 and placed in a new container-closure system that is not described in the approved labeling for  
182 the product, these additional manufacturing steps would create a new, unlicensed biological  
183 product. To be legally marketed, the new biological product would have to be licensed on the  
184 basis of an approved BLA that includes, among other things, chemistry and manufacturing  
185 controls data.

186

187

**C. Sections 503A and 503B of the FD&C Act Do Not Exempt Biological Products  
from the Premarket Approval Requirements of the PHS Act or from Provisions  
of the FD&C Act**

188

189

190

191

192

193

194

195

196

197

198

199

Section 503A of the FD&C Act exempts compounded drugs from sections 505 (concerning new drug approval of human drugs products), 502(f)(1) (concerning labeling of drug products with adequate directions for use), and 501(a)(2)(B) of the FD&C Act (concerning CGMP) provided that certain conditions are met, including that the drug is compounded pursuant to a prescription for an individually-identified patient from a licensed practitioner.

The Drug Quality and Security Act added a new section 503B to the FD&C Act. Under section 503B(b) of the FD&C Act, a compounder can register as an outsourcing facility with FDA. Drug products compounded under the direct supervision of a licensed pharmacist in an



***Contains Nonbinding Recommendations****Draft — Not for Implementation*

200 outsourcing facility can qualify for exemptions from the FDA approval requirements in section  
201 505 of the FD&C Act and the requirement to label drug products with adequate directions for use  
202 under section 502(f)(1) of the FD&C Act if the conditions in section 503B are met. Drugs  
203 compounded in outsourcing facilities are not exempt from the CGMP requirements of section  
204 501(a)(2)(B).

205

206 Although sections 503A and 503B provide an exemption for certain compounded drugs from the  
207 requirement to obtain premarket approval under section 505 of the FD&C Act, they do not  
208 provide an exemption from the requirement to obtain premarket approval under section 351 of  
209 the PHS Act. Manufacturers of biological products must obtain an approved license under  
210 section 351(a) or (k) of the PHS Act. Thus, for purposes of sections 503A and 503B, a *drug*  
211 does not include any biological product that is subject to licensure under section 351 of the PHS  
212 Act. Accordingly, such biological products are not eligible for the exemptions for compounded  
213 drugs under sections 503A and 503B of the FD&C Act. In other words, the FD&C Act does not  
214 provide a legal pathway for marketing biological products that have been prepared outside the  
215 scope of an approved BLA.

216

217 **D. Hospital and Health System<sup>8</sup> Repackaging of Drugs In Shortage For Use in the**  
218 **Health System (Section 506F of the FD&C Act)**

219

220 The Food and Drug Administration Safety and Innovation Act (FDASIA), signed into law in  
221 July, 2012, added section 506F to the FD&C Act. This section exempts certain hospitals within  
222 a health system from registration requirements in section 510 of the Act provided certain  
223 conditions are met, including that the drugs (including biological products) are, or have recently  
224 been, listed on FDA's drug shortage list<sup>9</sup> and are repackaged for the health system. Section 506F  
225 of the FD&C Act defines "repackaging," for purposes of that section only, as "divid[ing] the  
226 volume of a drug into smaller amounts in order to—(A) extend the supply of a drug in response  
227 to the placement of the drug on a drug shortage list under section 506E; and (B) facilitate access  
228 to the drug by hospitals within the same health system."

229

230 Section 506F of the FD&C Act has a termination clause that states "This section [506F] shall not  
231 apply on or after the date on which the Secretary issues a final guidance that clarifies the policy  
232 of the Food and Drug Administration regarding hospital pharmacies repackaging and safely  
233 transferring repackaged drugs [including drugs that are licensed biological products] to other  
234 hospitals within the same health system during a drug shortage."<sup>10</sup> These issues are addressed  
235 and clarified by this guidance, and the guidance on *Repackaging of Certain Human Drug*  
236 *Products by Pharmacies and Outsourcing Facilities*. Therefore, when these guidances become  
237 final, section 506F of the FD&C Act will no longer apply.

---

<sup>8</sup> For purposes of this guidance, the term "*health system*" refers to a collection of hospitals that are owned and operated by the same entity and that share access to databases with drug order information for their patients.

<sup>9</sup> See section 506F(b) (providing that the exemption may be available if, among other factors, the drug is repackaged (1) during any period in which the drug is listed on the drug shortage list under section 506E; or (2) during the 60-day period following any period described in paragraph (1)).

<sup>10</sup> See section 506F(d) of the FD&C Act.

***Contains Nonbinding Recommendations***

*Draft — Not for Implementation*

238

239 **III. POLICY**

240

241 Because biological products sometimes need to be mixed, diluted, or repackaged in ways not  
242 addressed in labeling approved for the product under section 351 of the PHS Act, but do not  
243 qualify for the exemptions in sections 503A or 503B of the FD&C Act, FDA has developed this  
244 guidance to explain the conditions under which FDA does not intend to take action when certain  
245 biological products are mixed, diluted, or repackaged in a manner not described in their approved  
246 labeling.

247

248 **A. General Conditions**

249

250 This guidance addresses the mixing, diluting, or repackaging of a licensed biological product, not  
251 a biological product licensed for further manufacturing use only, or a bulk drug substance. The  
252 policies expressed in this guidance do not extend to any person or entity that mixes, dilutes, or  
253 repackages a biological product from any other starting material. Consistent with section 351 of  
254 the PHS Act, a manufacturer seeking to mix, dilute, or repackage a biological product licensed  
255 for further manufacturing use only, or a bulk drug substance, must first submit a BLA and obtain  
256 a license for the product.

257

258 Furthermore, the policies expressed in this guidance apply only to the mixing, diluting, or  
259 repackaging of certain licensed biological products, in accordance with the conditions specified  
260 in sections III.B and III.C of this guidance. Except as described in sections III.B and III.C, the  
261 agency will consider regulatory action if a licensed biological product is subject to additional  
262 manufacturing, including mixing, diluting, or repackaging, outside of the conditions specified in  
263 the approved labeling for the licensed product.

264

265 As described in section B, a biological product that is mixed, diluted, or repackaged outside the  
266 scope of an approved BLA is an unlicensed biological product under section 351 of the PHS Act.  
267 To be legally marketed, the new biological product would have to be licensed on the basis of an  
268 approved BLA, have labeling with adequate directions for use, and be made in accordance with  
269 biological product standards and CGMP requirements. Therefore, biological products that do not  
270 meet the conditions in this guidance, including 1) biological products that are mixed, diluted, or  
271 repackaged by entities that are not state-licensed pharmacies, Federal facilities, or outsourcing  
272 facilities or 2) prescription sets of allergenic extracts that are not prepared by state-licensed  
273 pharmacies, Federal facilities, outsourcing facilities, or licensed physicians, must comply with  
274 requirements in the PHS Act, FD&C Act, and FDA regulations applicable to biological products  
275 manufactured by “conventional” manufacturers, including, but not limited to, biological product  
276 license requirements, and compliance with applicable standards and CGMP requirements.

277

278 **B. Mixing, Diluting, or Repackaging Licensed Biological Products**

279

***Contains Nonbinding Recommendations****Draft — Not for Implementation*

280 FDA does not intend to take action for violations of sections 351 of the PHS Act or 502(f)(1) of  
281 the FD&C Act if a state-licensed pharmacy, a Federal facility, or an outsourcing facility<sup>11</sup> mixes,  
282 dilutes, or repackages a biological product in accordance with the conditions described below,  
283 and any applicable requirements.<sup>12</sup> In addition, FDA does not intend to take action for violations  
284 of section 501(a)(2)(B) of the FD&C Act when a state-licensed pharmacy or a Federal facility  
285 mixes, dilutes, or repackages a biological product in accordance with the conditions described  
286 below, and any applicable requirements. Outsourcing facilities remain subject to applicable  
287 CGMP requirements.

288

289 The conditions referred to in the preceding paragraph are as follows:

290

- 291 1. The biological product that is mixed, diluted, or repackaged is an FDA-licensed biological  
292 product, not a biological product licensed for further manufacturing use only or a bulk drug  
293 substance.
- 294 2. The biological product is mixed, diluted, or repackaged in a state-licensed pharmacy, a  
295 Federal facility, or an outsourcing facility.
- 296 3. If the biological product is mixed, diluted, or repackaged in a state-licensed pharmacy or a  
297 Federal facility (but not an outsourcing facility), it is mixed, diluted, or repackaged after (a)  
298 the receipt of a valid prescription for an identified, individual patient directly from the  
299 prescribing practitioner, patient, or patient's agent; or (b) a written order in a patient's chart  
300 in a healthcare setting,<sup>13</sup> unless it is mixed, diluted, or repackaged (but not distributed) in  
301 advance of receipt of such a prescription or a written order in a patient's chart in a quantity  
302 that does not exceed the expected demand for the biological product within the beyond use  
303 date (BUD) on the product, based on a history of receipt of prescriptions or orders for such a  
304 biological product for that time period.
- 305 4. The biological product is mixed, diluted, or repackaged by or under the direct supervision of  
306 a licensed pharmacist.
- 307
- 308
- 309

---

<sup>11</sup> As we discuss in section II of this guidance, biological products licensed under section 351 of the PHS Act are not eligible for the statutory exemptions offered by sections 503A or 503B of the FD&C Act, and if a facility registers as an outsourcing facility but only mixes, dilutes, or repackages such biological products, none of the products made at the facility will be eligible for the exemptions under section 503B. However, this guidance describes the conditions under which FDA does not intend to take action for violations of section 351 of the PHS Act and sections 501(a)(2)(B) and 502(f)(1) of the FD&C Act if such biological products are mixed, diluted, or repackaged at a state-licensed pharmacy, a Federal facility, or an outsourcing facility that compounds drug products in accordance with section 503B.

<sup>12</sup> Applicable requirements include, for example, the requirement that manufacturers not adulterate a biological product by preparing, packing, or holding the drug under insanitary conditions. See section 501(a)(2)(A) of the FD&C Act.

<sup>13</sup> Drugs produced by outsourcing facilities, including drugs that are also biological products, remain subject to the requirements in section 503(b) of the FD&C Act. Therefore, a prescription drug, including a biological product, cannot be dispensed to a patient without a prescription.

***Contains Nonbinding Recommendations****Draft — Not for Implementation*

310

311 5. Except as provided below for a single dose vial, the biological product is mixed, diluted, or  
312 repackaged in a way that does not conflict with the approved labeling for the licensed  
313 biological product.<sup>14</sup>

314

315 For a biological product packaged in a single dose vial that is mixed, diluted, or repackaged  
316 into multiple units, the biological product is mixed, diluted, or repackaged in a way that does  
317 not conflict with the approved labeling, except for the statements designating the product as a  
318 single dose or single use product, and related language (e.g., discard remaining contents).<sup>15</sup>

319

320 6. As described in section II of this guidance, biological products are very susceptible to  
321 product quality concerns when mixed, diluted, or repackaged. For example, because  
322 biological products provide a rich media for microbial growth, they are particularly  
323 susceptible to microbial proliferation over time, if contaminated. Therefore, the mixed,  
324 diluted, or repackaged biological product is given a BUD that is not longer than the  
325 applicable BUD<sup>16</sup> below:

326

327 a. If the biological product is mixed, diluted, or repackaged by a state-licensed  
328 pharmacy or a Federal facility, it is given a BUD that  
329 - is not longer than 4 hours, or is equal to the time within which the opened product  
330 is to be used as specified in the approved labeling, whichever is shorter;<sup>17</sup> or

331 - is up to 24 hours if microbial challenge studies performed on the formulation of  
332 the diluted, mixed, or repackaged biological product in the type of container in  
333 which it will be packaged demonstrate that microbial growth will not progress to  
334 an unacceptable level within the period of the BUD. (See Appendix 1 for a  
335 description of microbial challenge study design.)

336 b. If the biological product is mixed or diluted by an outsourcing facility, it is given a  
337 BUD that

---

<sup>14</sup> For example, if the approved labeling for the licensed biological product contains instructions for handling or storage of the product, the mixing, diluting, or repackaging is done in accordance with those instructions. Otherwise, it would be considered to be in conflict with the approved labeling for the licensed biological product.

<sup>15</sup> For example, Avastin (bevacizumab) is packaged in a single dose vial. This condition could be satisfied even if Avastin is repackaged into multiple single dose syringes despite the fact that the label of the approved product states, "Single-use vial...Discard unused portion." However, this condition would not be satisfied if Avastin is mixed, diluted, or repackaged in a manner that conflicts with other language in the approved labeling (e.g., regarding the appropriate diluent and storage conditions).

<sup>16</sup> The BUD timeframes in this condition begin from the time in which the container of the original biological product to be repackaged or to be used for mixing or diluting is punctured or otherwise opened ("opened product").

<sup>17</sup> The 4 hour BUD timeframe in this guidance is consistent with the labeling of many licensed biological products, which require the disposal of any product not used within 4 hours after the product has been reconstituted or the container has been entered. Where another timeframe is provided in the labeling, it is based on data generated under specific conditions by the product's manufacturer and submitted with the BLA. Such data are not available for products mixed, diluted, or repackaged outside the scope of a BLA, as described in this guidance.

**Contains Nonbinding Recommendations***Draft — Not for Implementation*

- 338 - is not longer than 4 hours, or is equal to the time within which the opened product  
339 is to be used as specified on the approved labeling, whichever is shorter; or
- 340 - is up to 24 hours if microbial challenge studies performed on the formulation of  
341 the mixed or diluted biological product in the type of container in which it will be  
342 packaged demonstrate that microbial growth will not progress to an unacceptable  
343 level within the period of the BUD. (See Appendix 1 for a description of  
344 microbial challenge study design.)
- 345 c. If the biological product is repackaged by an outsourcing facility, it is given a BUD  
346 that
- 347 - is not longer than 4 hours, or is equal to the time within which the opened product  
348 is to be used as specified on the approved labeling, whichever is shorter; or
- 349 - is up to 24 hours if microbial challenge studies performed on the formulation of  
350 the repackaged biological product in the type of container in which it will be  
351 packaged demonstrate that microbial growth will not progress to an unacceptable  
352 level within the period of the BUD. (See Appendix 1 for a description of  
353 microbial challenge study design); or
- 354 - does not exceed 5 days or the expiration date of the biological product being  
355 repackaged, whichever is shorter, provided that the outsourcing facility conducts  
356 adequate compatibility studies on the container-closure system (e.g., the syringe)  
357 of the repackaged biological product to demonstrate compatibility and ensure  
358 product integrity. (See Title 21, section 211.94 of the Code of Federal  
359 Regulations for regulations on drug product containers and closures).<sup>18</sup>
- 360 7. If the biological product is mixed, diluted, or repackaged in a state-licensed pharmacy or a  
361 Federal facility, it is done in accordance with the United States Pharmacopeia (USP) Chapter  
362 <797>, except the BUD is as specified in condition 6; if the biological product is mixed,  
363 diluted, or repackaged in an outsourcing facility, it is done in accordance with CGMP  
364 requirements, except the BUD is as specified in condition 6.  
365
- 366 8. The biological product is not sold or transferred by an entity other than the entity that mixed,  
367 diluted, or repackaged the biological product. For purposes of this condition, a sale or  
368 transfer does not include administration of a biological product in a health care setting.  
369

---

<sup>18</sup> This longer BUD reflects that outsourcing facilities must comply with CGMP requirements and are subject to FDA inspections on a risk-based schedule. Conditions maintained to comply with CGMP requirements provide greater assurance of the quality of manufacturing operations and the products that are produced at the facility. This longer BUD is not provided for mixed or diluted biological products because these activities are more likely to alter the characteristics of the biological product in ways that could harm patients, even if performed under CGMP conditions. To provide a sufficient basis for FDA to conclude that a longer BUD on a mixed or diluted product was justified, an outsourcing facility would need to submit a BLA that included data on the impacts of diluting or mixing the specific product.

***Contains Nonbinding Recommendations****Draft — Not for Implementation*

- 370 9. The mixed, diluted, or repackaged biological product is distributed only in states in which the  
371 facility mixing, diluting, or repackaging the biological product meets any applicable state  
372 requirements.  
373
- 374 10. If the biological product is mixed, diluted, or repackaged by an outsourcing facility:  
375
- 376 a. The label on the immediate container (primary packaging, e.g., the syringe) of the  
377 mixed, diluted, or repackaged biological product includes the following:
- 378 i. The statement “This biological product was mixed/diluted by [name of  
379 outsourcing facility],” or “This product was repackaged by [name of  
380 outsourcing facility],” whichever statement is appropriate
  - 381 ii. The address and phone number of the outsourcing facility that mixed, diluted,  
382 or repackaged the biological product
  - 383 iii. The proper name of the original biological product that was mixed, diluted, or  
384 repackaged
  - 385 iv. The lot or batch number assigned by the outsourcing facility for the mixed,  
386 diluted, or repackaged biological product
  - 387 v. The dosage form and strength of the mixed, diluted, or repackaged biological  
388 product
  - 389 vi. A statement of either the quantity or the volume of the mixed, diluted, or  
390 repackaged biological product, whichever is appropriate
  - 391 vii. The date the biological product was mixed, diluted, or repackaged
  - 392 viii. The BUD of the mixed, diluted, or repackaged biological product
  - 393 ix. Storage and handling instructions for the mixed, diluted, or repackaged  
394 biological product
  - 395 x. The National Drug Code (NDC) number of the mixed, diluted, or repackaged  
396 biological product, if available<sup>19</sup>
  - 397 xi. The statement “Not for resale,” and, if the biological product is distributed by  
398 an outsourcing facility other than pursuant to a prescription for an individual  
399 identified patient, the statement “Office Use Only”
  - 400 xii. If included on the label of the FDA-licensed biological product from which  
401 the biological product is being mixed, diluted, or repackaged, a list of the  
402 active and inactive ingredients, unless such information is included on the  
403 label for the container from which the individual units are removed, as  
404 described below in 10.b.i; and if the biological product is mixed or diluted, the  
405 label of the mixed or diluted product includes any ingredients that appear in  
406 the mixed or diluted product in addition to those ingredients that are on the  
407 original FDA-licensed biological product.
- 408
- 409 b. The label on the container from which the individual units are removed for  
410 administration (secondary packaging, e.g., the bag, box, or other package in which the  
411 mixed, diluted, or repackaged biological products are distributed) includes:

---

<sup>19</sup> The NDC number of the original licensed biological product should not be placed on the mixed, diluted, or repackaged biological product.

**Contains Nonbinding Recommendations***Draft — Not for Implementation*

- 412 i. The active and inactive ingredients, if the immediate product label is too small  
413 to include this information
- 414 ii. Directions for use, including, as appropriate, dosage and administration, and  
415 the following information to facilitate adverse event reporting:  
416 [www.fda.gov/medwatch](http://www.fda.gov/medwatch) and 1-800-FDA-1088.  
417
- 418 c. Each mixed, diluted, or repackaged biological product is also accompanied by a copy  
419 of the prescribing information that accompanied the original FDA-licensed biological  
420 product that was mixed, diluted, or repackaged.  
421
- 422 d. The mixed, diluted, or repackaged biological product is included on a report  
423 submitted to FDA each June and December identifying the drug products made by the  
424 outsourcing facility during the previous 6-month period, including: a notation that this  
425 is a mixed, diluted, or repackaged biological product; the active ingredient; the source  
426 of the active ingredient; NDC number of the source ingredient, if available; strength  
427 of the active ingredient per unit; the dosage form and route of administration; the  
428 package description; the number of individual units mixed, diluted, or repackaged<sup>20</sup>;  
429 and the NDC number of the final product, if assigned.<sup>21</sup>  
430
- 431 e. The outsourcing facility reports serious adverse events to FDA that may be associated  
432 with its mixed, diluted, or repackaged biological products.  
433

**C. Licensed Allergenic Extracts**

434  
435  
436 FDA recognizes that there are circumstances in which licensed allergenic extracts would be  
437 mixed and diluted to provide subcutaneous immunotherapy to an individual patient, even though  
438 these allergenic extract combinations are not specified in the approved BLAs for the licensed  
439 biological products. Such combinations are commonly referred to as prescription sets.<sup>22</sup> For the  
440 purpose of this guidance a *prescription set* is defined as a vial or set of vials of premixed licensed  
441 standardized and non-standardized allergenic extracts for subcutaneous immunotherapy diluted  
442 with an appropriate diluent prepared according to instructions from a prescription or order by a  
443 licensed physician for an individual patient.

---

<sup>20</sup> Currently, FDA's electronic drug reporting system is not configured to accept additional information that is specific to biological products, such as license number. In the future, FDA intends to modify the system to accept this information.

<sup>21</sup> FDA has issued a draft guidance for industry, *Electronic Drug Product Reporting for Human Drug Compounding Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act*, which prescribes how human drug compounding facilities are to submit drug product reports to FDA. Although this guidance addresses reporting of compounded human drug products, outsourcing facilities should follow the same procedure to electronically report the biological products they mixed, diluted, or repackaged.

<sup>22</sup> Under 21 CFR 610.17, licensed biological products must not be combined with other licensed biological products; either therapeutic, prophylactic or diagnostic, except as covered by a license obtained for the combined product. All mixes of allergenic extracts that are not prescription sets must be the subject of an approved BLA, or have in effect an investigational new drug application.

***Contains Nonbinding Recommendations****Draft — Not for Implementation*

444

445 FDA does not intend to take action for violations of section 351 of the PHS Act or section  
446 502(f)(1) of the FD&C Act if a physician, state-licensed pharmacy, a Federal facility, or  
447 outsourcing facility prepares prescription sets of allergenic extracts in accordance with the  
448 conditions described below, and any applicable requirements.<sup>23</sup>

449

450 In addition, with respect to a prescription set prepared in accordance with the following  
451 conditions and any applicable requirements, FDA does not intend to take action for violations of  
452 section 501(a)(2)(B) of the FD&C Act when the prescription set is prepared by a physician,  
453 state-licensed pharmacy, or a Federal facility in accordance with the conditions described below;  
454 outsourcing facilities remain subject to applicable CGMP requirements.

455

456 The conditions referred to in the preceding paragraph are as follows:

457

- 458 1. The prescription set is prepared from FDA-licensed allergenic extracts and appropriate  
459 diluents.
- 460 2. The prescription set is prepared in a in a physician's office, state-licensed pharmacy, a  
462 Federal facility, or outsourcing facility.
- 463 3. If the prescription sets are prepared in a physician's office, state-licensed pharmacy, or a  
464 Federal facility (but not an outsourcing facility), each set is prepared after (a) the receipt of a  
465 valid prescription for an identified, individual patient directly from the prescribing  
466 practitioner, patient, or patient's agent; or (b) a written order in a patient's chart, unless it is  
467 prepared in advance of receipt of such a prescription or a written order in a quantity that does  
468 not exceed the expected demand for that prescription set within the BUD for the product,  
469 based on a history of receipt of prescriptions or orders for such a prescription set for that  
470 time period. If the prescription sets are prepared in an outsourcing facility, those sets are  
471 prepared either after, or in anticipation of, receiving valid prescriptions for an identified,  
472 individual patient or a written order in a patient's chart.
- 473 4. The prescription set is distributed to a physician or to a health system for use within the  
475 health system only after the receipt of a valid prescription for an identified, individual patient  
476 or a written order in a patient's chart.
- 477 5. The prescription set is prepared in a way that does not conflict with approved labeling of the  
478 licensed biological products that are part of the prescription set.<sup>24</sup>
- 479 6. The BUD for the prescription set is no later than the earliest expiration date of any allergenic  
480 extract or any diluent that is part of the prescription set.
- 481
- 482
- 483
- 484

---

<sup>23</sup> See note 12.

<sup>24</sup> See note 15.



***Contains Nonbinding Recommendations****Draft — Not for Implementation*

- 485 7. If the prescription set is prepared in a state-licensed pharmacy or a Federal facility, or in a  
486 physician’s office, it is prepared in accordance with USP Chapter <797>, except the BUD is  
487 as specified in condition 6; if the prescription set is prepared in an outsourcing facility, it is  
488 prepared in accordance with applicable CGMP requirements, except the BUD is as specified  
489 in condition 6.  
490
- 491 8. The prepared prescription set is not sold or transferred by an entity other than the entity that  
492 prepared the prescription set. For purposes of this condition, a sale or transfer does not  
493 include administration of a prescription set in a health care setting.  
494
- 495 9. The prescription set is distributed<sup>25</sup> only in states in which the facility preparing the  
496 prescription set meets any applicable state requirements.  
497
- 498 10. If the prescription set is prepared by an outsourcing facility:  
499
- 500 a. The label on the immediate container(s) (primary packaging) of the prescription set  
501 includes the following:  
502 i. The patient’s name as identified on the prescription  
503 ii. The statement “This prescription set was prepared by [name of outsourcing  
504 facility]”  
505 iii. The address, and phone number of the outsourcing facility that prepared the  
506 prescription set  
507 iv. The identity of each allergenic extract in the prescription set, and the quantity  
508 of each  
509 v. The dilution of each dilution vial  
510 vi. The lot or batch number of the prescription set  
511 vii. The date the prescription set was prepared  
512 viii. The BUD of the prescription set  
513 ix. Storage and handling instructions for the prescription set  
514 x. The statement “Not for resale”  
515
- 516 b. The label of the container from which the individual units of the prescription set are  
517 removed for administration (secondary packaging) includes the following information  
518 to facilitate adverse event reporting: [www.fda.gov/medwatch](http://www.fda.gov/medwatch) and 1-800-FDA-1088.  
519
- 520 c. Each prescription set also is accompanied by instructions for use and the FDA  
521 approved package insert for each allergenic extract.  
522
- 523 d. The prescription set is included in a report submitted to FDA each June and  
524 December identifying the drug products made by the outsourcing facility during the  
525 previous 6-month period, including: a notation that this is a biological product; the  
526 active ingredient(s); source of the active ingredient(s); NDC number of the source  
527 ingredient(s), if available; strength of the active ingredient(s) per unit; the dosage

---

<sup>25</sup> *Distribution* means that the prepared prescription set has left the facility in which it was prepared.

***Contains Nonbinding Recommendations****Draft — Not for Implementation*

- 528 form and route of administration; the package description; the number of individual  
529 units produced; and the NDC number of the final product, if assigned.<sup>26</sup>  
530
- 531 e. The outsourcing facility reports serious adverse events to FDA that may be associated  
532 with its prescription sets.  
533

---

<sup>26</sup> FDA has issued a draft guidance for industry, *Electronic Drug Product Reporting for Human Drug Compounding Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act*, which prescribes how human drug compounding facilities are to submit drug product reports to FDA. Once finalized, that guidance will represent the Agency’s thinking on that topic. Although this guidance addresses reporting of compounded human drug products, outsourcing facilities should follow the same procedure to electronically report the prescription sets they prepared.

**Contains Nonbinding Recommendations**

Draft — Not for Implementation

**APPENDIX 1 — MICROBIAL CHALLENGE STUDY DESIGN**

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

The following design recommendations for product growth promotion studies should be followed to extend the BUD to up to 24 hours for a mixed, diluted, or repackaged biological product as referenced in Section II. B.

Microbial challenge studies are designed to demonstrate that the product in question does not support adventitious microbial growth under the proposed storage conditions. Each facility would conduct a microbial challenge study at least once for each mixed, diluted, or repackaged biological product, to demonstrate that the microbial quality of the biological product mixed, diluted, or repackaged by that facility can be ensured. The microbial challenge study should be repeated if the formulation or the container-closure system is changed. The studies should be accurately documented and records maintained for inspection.

The challenge microbes should include the panel provided in USP<51> Antimicrobial Effectiveness Testing.<sup>27</sup> These strains represent the species *Escherichia coli*, *Pseudomonas aeruginosa*, *Staphylococcus aureus*, *Candida albicans* and *Aspergillus brasiliensis* (formerly *Aspergillus niger*). It should also incorporate typical skin microflora and nosocomial agents to simulate the types of flora that may contaminate a drug product in a healthcare setting. Finally, the challenge should include strains of the tribe *Klebsielleae*, as they have been shown to proliferate in infusion products.<sup>28</sup>

Individual containers of the mixed, diluted, or repackaged biological product should be inoculated with each challenge organism, with each container receiving one type of organism. The inoculum size should be small but also measurable and repeatable. For example, if a membrane filtration method is used to quantify the number of organisms, an inoculum size of fewer than 100 CFU/mL is appropriate.

Following inoculation of the final product with the challenge organisms, the test units should be stored at the temperature(s) described in the biological product's labeling. Samples should be removed periodically throughout the duration of the study for determination of microbial count for up to 72 hours (3 times the maximum BUD). To support a BUD of 24 hours, each challenge organism should demonstrate no increase from the initial count (where *no increase* is defined as not more than 0.5 log<sub>10</sub> unit higher than the initial inoculum at any time point up to 72 hours) and no evidence of growth. As explained in the example below, data from a study of 72 hours' duration should be examined for trending and to establish a maximum storage time of up to 24 hours at a specified temperature.

**Example: Determination of Microbial Growth**

<sup>27</sup> USP51/NF26. United States Pharmacopeial Convention, 2008.


<sup>28</sup> See, Mahl, M.C., et al. Nitrogen Fixation by Members of the Tribe *Klebsielleae*, *J. Bacteriol.*, 1965, 89(6): 1482; Maki, D., et al., Infection Control in Intravenous Therapy, *Annals of Internal Medicine*, 1973, 79: 867.

**Contains Nonbinding Recommendations**  
*Draft — Not for Implementation*

574 The following table represents data from a hypothetical microbial challenge experiment where  
 575 the inoculum is less than 100 CFU/mL, and the requested maximum hold time is equivalent to  
 576 Time Point 4.  
 577

Time	Microbial Count (CFU/mL)	Log of Microbial Count
1	88	1.9
2	95	2
3	98	2
4	220	2.3
5	552	2.7

578  
 579 These data reflect *no increase* from the initial count through Time Point 4. However, as  
 580 illustrated in Figure 1 below, the semi-logarithmic graph of CFU/mL vs. Time shows clear  
 581 evidence of growth of the challenge organism at Time Point 4.  
 582  
 583



584  
 585 Thus, a maximum hold time equivalent to that of Time Point 4 would pose potential risk to the  
 586 microbiological quality of the hypothetical mixed, diluted, or repackaged biological product, and  
 587 the acceptable BUD would be set at one-third of Time Point 3. It is also important to note that, if  
 588 the experiment were concluded at Time Point 4, the ability to predict the trend of the data would  
 589 be lost. As presented in the graphic, the growth trend appears to signal the start of log-phase  
 590 growth, which could occur earlier or later with different strains of a given species. Such growth  
 591 would produce exponential increases in the microbial population that pose significant risk to  
 592 patients. This concern is the reason for periodic sampling when determining microbial  
 593 concentration.  
 594